Skip To Main Content
Skip To Main Content

Kisor to present in Italy

Dr. David Kisor, professor of pharmacokinetics, was involved in the development of the drug nelarabine, a guanine derivative, used in the treatment of T-cell lymphoma and leukemia, a form of cancer that attacks the white blood cells. In September, Kisor will present a review of nelarabine at an international conference, 2009 - 2012 T-Cell Lymphomas: work in progress, held in Bologna, Italy.

The drug, originally synthesized in 1978 at Burroughs Welcome Co., now GlaxoSmithKline, progressed through the drug development process and was made available for use in 2005 in the U.S. and in 2007 in Europe. The drug has the potential to put patients into complete remission and additionally has allowed patients to undergo other treatments such as bone marrow transplantation, with the hope of a sustained response leading to a cure of the disease.

Kisor came to ONU from GlaxoWellcome where he was a research scientist in pharmacokinetics and drug metabolism, being involved in the development of purine analog anti-leukemia drugs, including nelarabine. He teaches pharmacokinetics and pharmacogenetics and is the chair of the Department of Pharmaceutical and Biomedical Sciences in the Raabe College of Pharmacy. 

The Italian conference includes 60 researchers/academicians/clinicians from around the globe for three days of presentations on state-of-the-art diagnosis and treatment of T-cell lymphoma. Kisor will speak on the third day of the event as part of the therapy section dealing with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.